We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Short Half-Life of Des-γ-Carboxy Prothrombin Is a Superior Factor for Early Prediction of Outcomes of Hepatocellular Carcinoma Treated with Radiofrequency Ablation.
- Authors
Yao, Chih-Chien; Wang, Jing-Houng; Chen, Chien-Hung; Hung, Chao-Hung; Yen, Yi-Hao; Kee, Kwong-Ming; Hu, Tsung-Hui; Tsai, Ming-Chao; Kuo, Yuan-Hung; Lu, Sheng-Nan
- Abstract
Background: The role of des-γ-carboxy prothrombin (DCP) in patients undergoing radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) needs to be clarified. Materials and methods: 174 HCC patients that underwent RFA were enrolled. We calculated the HLs of DCP from the available values before and on first day after ablation and assessed the correlation between HLs of DCP and RFA efficacy. Results: Of 174 patients, 63 with pre-ablation DCP concentrations of ≥80 mAU/mL were analyzed. The ROC analysis showed the optimal cut-off value of HLs of DCP for predicting RFA response was 47.5 h. Therefore, we defined short HLs of DCP < 48 h as a predictor of favorable treatment response. Of 43 patients with a complete radiological response, 34 (79.1%) had short HLs of DCP. In 36 patients with short HLs of DCP, 34 (94.4%) had a complete radiologic response. The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 79.1%, 90.0%, 82.5%, 94.4%, and 66.7%. During the 12-month follow-up, patients who had short HLs of DCP had a better disease-free survival rate than patients with long HLs of DCP (p < 0.001). Conclusions: Short HLs of DCP < 48 h calculated on the first day post-RFA are a useful predictor for treatment response and recurrence-free survival after RFA.
- Subjects
CATHETER ablation; HEPATOCELLULAR carcinoma; PROTHROMBIN; PROGRESSION-free survival; SURVIVAL rate
- Publication
Diagnostics (2075-4418), 2023, Vol 13, Issue 4, p696
- ISSN
2075-4418
- Publication type
Article
- DOI
10.3390/diagnostics13040696